<p class="MsoNormal">As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:</p> <ol style="margin-top: 0in;" start="1" type="1"> <li class="MsoListParagraph" style= "margin-top: 0in; margin-bottom: 0in; line-height: 11.55pt; font-size: 12pt;"> What are the unmet needs in 1L therapy?</li> <li class="MsoListParagraph" style= "margin-top: 0in; margin-bottom: 0in; line-height: 11.55pt; font-size: 12pt;"> The KRAS G12C mutation landscape</li> </ol>

As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics: What are the unmet needs in 1L therapy? The KRAS G12C mutation landscape

<p>As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:</p> <ol> <li> What are the unmet needs in 1L therapy?</li> <li> The KRAS G12C mutation landscape</li> </ol>

Ep.3 What We're Watching at ASCO 2024

Bluestar BioAdvisors team shares insights on drug pipelines and predicts industry trends. Each episode is hosted by a senior member of our New York City based life sciences consulting firm. The host is typically joined by an external expert guest, with whom the host expands on their experiences providing insights and recommendations for industry leaders and emergent innovators, and translating the data of today into the implications for business of science of tomorrow.

Share Ep.3 What We're Watching at ASCO 2024

Sign up to save your podcasts

Ep.3 What We're Watching at ASCO 2024

Ep.3 What We're Watching at ASCO 2024